

## General Information

Name: Dr. med. Eugen Tausch  
Date of Birth: 23.08.1983  
Gender: Male  
Address: Department of Internal Medicine III, Ulm University Hospital,  
Albert-Einstein-Allee 23, 89081 Ulm, Germany  
Phone: +49 731 500 45729  
Fax: +49 731 500 45525  
E-Mail: eugen.tausch@uniklinik-ulm.de  
Current Position: Resident and postdoctoral research fellow at the Department of  
Internal Medicine III

## Academic Education

2010 Medical Licensing Examination, University of Regensburg  
2004-2010 Medical School, University of Regensburg

## Academic Degrees

2013 Doctoral Thesis (*Dr. med.*) (University of Regensburg)

## Professional Experience

Since 2015 Residency/Fellowship, Department of Internal Medicine III (Prof. H. Döhner), Ulm University Hospital  
2013-2015 Postdoctoral fellowship at Central Reference Laboratory for Genetics (Prof. S. Stilgenbauer / Prof. H. Döhner), Ulm University, (Clinician Scientist Scholarship of the Else Kröner Fresenius Stiftung)  
2011-2013 Residency, Department of Internal Medicine III (Prof. H. Döhner), Ulm University Hospital

## Miscellaneous

### Awards and Honors:

2019 Best abstract by a young investigator, ICML (Lugano, Switzerland)  
2017 Best abstract award, iwCLL2017 (New York, USA)  
2013-2015 Clinician scientist scholarship of the Else Kröner Fresenius Stiftung

## Publications

1. Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, Bahlo J, Al-Sawaf O, Ritgen M, Fink AM, Eichhorst B, Kreuzer KA, Tandon M, Humphrey K, Jiang Y, Schary W, Bullinger L, Mertens D, Porro Lurà M, Kneba M, Döhner H, Fischer K, Hallek M, Stilgenbauer S. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. **Blood** 2020 Jun 25;135(26):2402–12.
2. Maity PC, Bilal M, Koning MT, Young M, van Bergen CAM, Renna V, Nicolò A, Datta M, Gentner-Göbel E, Barendse RS, Somers SF, de Groen RAL, Vermaat JSP, Steinbrecher D, Schneider C, Tausch E, Bittolo T, Bomben R, Mazzarello AN, Del Poeta G, Kroes WGM, van Wezel JT, Imkeller K, Busse CE, Degano M, Bakchoul T, Schulz AR, Mei H, Ghia P, Kotta K, Stamatopoulos K, Wardemann H, Zucchetto A, Chiorazzi N, Gattei V, Stilgenbauer S, Veelken H, Jumaa H. IGLV3-21\* is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. **Proc Natl Acad Sci USA**. 2020 Feb 11;117(8):4320-4327
3. Tausch E, Beck P, Schlenk RF, Jebaraj BJ, Dolnik A, Yosifov DY, Hillmen P, Offner F, Janssens A, Babu KG, Grosicki S, Mayer J, Panagiotidis P, McKeown A, Gupta IV, Skorupa A, Pallaud C, Bullinger L, Mertens D, Döhner H, Stilgenbauer S. Prognostic and predictive role of gene mutations

- in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. **Haematologica**. 2020 Jan 9 105(10):2440-2447
4. Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, Döhner H, Mertens D, Stilgenbauer S. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. **Haematologica**. 2019 Sep;104(9):e434-e437
  5. Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. **N Engl J Med**. 2019 Jun 6;380(23):2225-2236.
  6. Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S. Final Results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. **J Clin Oncol**. 2019 Jun 1;37(16):1391-1402.
  7. Close V, Close W, Kugler SJ, Reichenzeller M, Yosifov DY, Bloehdorn J, Pan L, Tausch E, Westhoff MA, Döhner H, Stilgenbauer S, Oswald F, Mertens D. FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. **Blood**. 2019 Feb 21;133(8):830-839.
  8. Malcikova J\*, Tausch E\*, Rossi D\*, Sutton LA, Soussi T, Zenz T, Kater AP, Niemann CU, Gonzalez D, Davi F, Gonzalez Diaz M, Moreno C, Gaidano G, Stamatopoulos K, Rosenquist R, Stilgenbauer S, Ghia P, Pospisilova S; European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. **Leukemia**. 2018 May;32(5):1070-1080
  9. Tiao G, Improgo MR, Tausch E, Fernandes SM, Bahlo J, Robrecht S, Fischer K, Hallek M, Stilgenbauer S, Kiezun A, Getz G, Brown JR. Analysis of ITGB2 rare germline variants in chronic lymphocytic leukemia. **Blood**. 2017 Nov 30;130(22):2443-2444.
  10. Landau DA\*, Tausch E\*, Taylor-Weiner AN\*, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edlmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ. Mutations driving CLL and their evolution in progression and relapse. **Nature**. 2015 Oct 22;526(7574):525-30